Oncorn Medcorp Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -45.72%
- Profit Growth -336.76%
- Ebitda -264.39%
- Net Worth -214.37%
- Total Assets -78.34%
About Oncorn Medcorp
Oncorn Medcorp Private Limited (OMPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 August 2020 (Four years and six months 16 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suma Radheshyam and Rajeev Nagi serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999KA2020PTC136918
- Company No.
136918
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Aug 2020
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Oncorn Medcorp?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Nagi  | Director | 06-Aug-2020 | Current |
| Suma Radheshyam | Director | 06-Aug-2020 | Current |
Financial Performance of Oncorn Medcorp.
Oncorn Medcorp Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 45.72% decrease. The company also saw a substantial fall in profitability, with a 336.76% decrease in profit. The company's net worth observed a substantial decline by a decrease of 214.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oncorn Medcorp?
In 2022, Oncorn Medcorp had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Beauty Hut Private LimitedSuma Radheshyam is a mutual person
- Sammprada Medcare Private Limited
Suma Radheshyam is a mutual person
- Ss Salon Point Private Limited
Suma Radheshyam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oncorn Medcorp?
Oncorn Medcorp has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oncorn Medcorp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oncorn Medcorp's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.